D. Vassilief

428 total citations
11 papers, 292 citations indexed

About

D. Vassilief is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, D. Vassilief has authored 11 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Genetics and 2 papers in Rheumatology. Recurrent topics in D. Vassilief's work include Acute Myeloid Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). D. Vassilief is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). D. Vassilief collaborates with scholars based in France. D. Vassilief's co-authors include Pierre Fenaux, François Dreyfus, Agnès Guerci, Odile Beyne‐Rauzy, Aspasia Stamatoullas, Christian Rosé, Sabine Bréchignac, Laurent Pascal, Stéphane Chèze and Pierre Morel and has published in prestigious journals such as Blood, British Journal of Haematology and Haemophilia.

In The Last Decade

D. Vassilief

10 papers receiving 286 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Vassilief France 6 262 190 42 26 22 11 292
Ana Cristina Silva‐Pinto Brazil 9 155 0.6× 182 1.0× 14 0.3× 3 0.1× 40 1.8× 21 242
Madhuri Vusirikala United States 7 129 0.5× 48 0.3× 55 1.3× 5 0.2× 15 0.7× 28 191
Judith Marsh United Kingdom 3 251 1.0× 132 0.7× 22 0.5× 3 0.1× 22 1.0× 6 302
Concepción Rivas Spain 7 262 1.0× 35 0.2× 126 3.0× 7 0.3× 19 0.9× 18 353
Elineema Meda Tanzania 6 347 1.3× 401 2.1× 15 0.4× 2 0.1× 30 1.4× 7 437
Clémence Mediavilla France 8 88 0.3× 31 0.2× 26 0.6× 4 0.2× 10 0.5× 18 137
Maria Grazia Orofino Italy 8 235 0.9× 235 1.2× 53 1.3× 2 0.1× 33 1.5× 12 363
Gérard Couillaud France 7 127 0.5× 27 0.1× 42 1.0× 11 0.4× 21 1.0× 8 216
Kyle Hebert United States 6 143 0.5× 78 0.4× 14 0.3× 3 0.1× 25 1.1× 13 191
Canan Albayrak Türkiye 8 68 0.3× 22 0.1× 27 0.6× 5 0.2× 21 1.0× 21 152

Countries citing papers authored by D. Vassilief

Since Specialization
Citations

This map shows the geographic impact of D. Vassilief's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Vassilief with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Vassilief more than expected).

Fields of papers citing papers by D. Vassilief

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Vassilief. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Vassilief. The network helps show where D. Vassilief may publish in the future.

Co-authorship network of co-authors of D. Vassilief

This figure shows the co-authorship network connecting the top 25 collaborators of D. Vassilief. A scholar is included among the top collaborators of D. Vassilief based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Vassilief. D. Vassilief is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Rosé, Christian, Sabine Bréchignac, D. Vassilief, et al.. (2010). Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leukemia Research. 34(7). 864–870. 144 indexed citations
2.
Tamburini, Jérôme, C. Elie, Sophie Park, et al.. (2008). Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leukemia Research. 33(4). 547–550. 11 indexed citations
3.
Rosé, Christian, Sabine Bréchignac, D. Vassilief, et al.. (2007). Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.. Blood. 110(11). 249–249. 57 indexed citations
4.
Rosé, Christian, A. Stamatoulas, D. Vassilief, et al.. (2006). RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.. Blood. 108(11). 2661–2661.
5.
Tamburini, Jérôme, C. Elie, D. Vassilief, et al.. (2006). Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.. Blood. 108(11). 2673–2673. 1 indexed citations
8.
Bouscary, Didier, D. Vassilief, Achille Aouba, et al.. (2004). Thalidomide for the Treatment of Low Risk Myelodysplasia.. Blood. 104(11). 1438–1438. 3 indexed citations
9.
Mannone, Lionel, Claude Gardin, J. F. Bernard, et al.. (2004). High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.. Blood. 104(11). 69–69. 11 indexed citations
10.
Bouscary, Didier, Katayoun Jondeau, F Viguié, et al.. (1999). Aplastic Anemia Responsive to Cyclosporine Complicating the Evolution of Polycythemia Vera. Leukemia & lymphoma. 33(5-6). 607–611. 2 indexed citations
11.
Ginsburg, Charles M., Dominique Salmon‐Céron, D. Vassilief, et al.. (1997). Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment.. PubMed. 11(3). 388–9. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026